SC
Therapeutic Areas
Ironwood Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LINZESS (linaclotide) | Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) | Approved |
| Apraglutide | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Phase 3 |
Leadership Team at Ironwood Pharmaceuticals
TM
Thomas McCourt
Chief Executive Officer
MS
Michael Shetzline
Senior Vice President, Chief Medical Officer and Head of Research and Development
AW
Anthony Wajda
Regional Sales Manager
CB
Christine Brackins
Clinical Sales Specialist